



REBLOZYL is a registered trademark of Celgene Corporation used under license by Celgene Inc.
REBLOZYL logo is a trademark of Celgene Corporation used under license by Celgene Inc.

© 2021 Celgene Corporation

I have been prescribed REBLOZYL

Important Contact Information

My healthcare professional who prescribed REBLOZYL:

Name: _____

Office phone number: _____

Institution address: _____



PATIENT CARD
(For women of
childbearing potential)

This material was developed by Celgene Inc., a Bristol Myers Squibb company, as part of the risk minimization plan for REBLOZYL®.

This material is not intended for promotional use.

Date of internal approval: December 2020
2007CA2000448E

PATIENT INFORMATION

REBLOZYL (luspatercept) should not be used during pregnancy. REBLOZYL may cause harm to your unborn baby.

Do not use REBLOZYL if you are pregnant or breast-feeding, or could become pregnant and are not using an effective method of birth control.

- Before starting treatment with REBLOZYL:
 1. Your healthcare professional may arrange a pregnancy test.
 2. You must discuss effective methods of birth control with your doctor and use an effective method of birth control while taking REBLOZYL and for at least 3 months after stopping treatment with REBLOZYL.
- Tell your doctor right away if you are pregnant or think you might be pregnant during treatment with REBLOZYL or for 3 months after stopping REBLOZYL.

Please see the back of this reminder card for your prescriber's contact information.

For more information about the effects and side effects of REBLOZYL, please refer to the Patient Medication Information for REBLOZYL: https://www.bms.com/assets/bms/ca/documents/productinformation/REBLOZYL_EN_PIL.pdf

For more information or to obtain a copy of this document, visit BMS Canada Website or contact medical information by calling **1-866-463-6267**.